Developer docs
API playgroundTry for free, no card

Search company profiles

Quantoom Biosciences

Full company profile

uuid0009zuq

Namestring
Quantoom Biosciences
Websiteurl
quantoom.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Quantoom Biosciences is a Belgium-based, privately held biotechnology company founded in 2021 that develops proprietary RNA production and formulation technologies for mRNA vaccine and therapeutic manufacturing. The company's core platform combines microfluidic and robotics-based automation with its registered Ntensify® product family — Ntensify® mano for research-scale RNA synthesis and Ntensify® micro for compact-scale workflows — and is being extended with Ncapsulate® LNP (lipid nanoparticle) formulation kits that encapsulate RNA for delivery. Together these products form an integrated RNA production-to-formulation workflow aimed at researchers developing next-generation RNA applications and therapeutics, with a particular emphasis on personalized cancer vaccines.

The company operates a hybrid revenue model anchored in hardware sales of its Ntensify® kits and Ncapsulate® LNP kits, supplemented by professional-services revenue from co-development and manufacturing collaborations in personalized mRNA cancer vaccines. Go-to-market is channel-led: a pan-European distribution partnership with Europa Biosite (announced March 2026) drives research-customer reach across Europe, while flagship academic reference-site partnerships — the RNA Innovation Foundry at the University of Western Australia (April 2025) and the University of Arizona Center for Advanced Molecular and Immunological Therapies (February 2026) — function as both validation anchors and co-development partners. The company is headquartered in Nivelles, Belgium, employs 101-250 people, and is led by CEO José Castillo.

Short descriptiontext

Quantoom Biosciences is a Belgium-based biotech that develops proprietary microfluidic and robotics-based RNA production and LNP formulation technologies, selling Ntensify® kits and Ncapsulate® reagents to academic and research customers developing mRNA vaccines and therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNivelles, Belgium
HQ citystring
Nivelles
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA production technology, mRNA manufacturing, lipid nanoparticle formulation, biotech research tools, personalized cancer vaccines
Industry4 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA Production Technology
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1RNA Production Technologies
TypeHardware Sales
Description

Sale and distribution of Ntensify® mano and Ntensify® micro RNA production technologies to researchers across Europe through distribution partnerships

biotechniques.com
2LNP Formulation Kits
TypeHardware Sales
Description

Sale of Ncapsulate® LNP formulation kits for RNA delivery applications as they become commercially available

biotechniques.com
3mRNA Vaccine Manufacturing Services
TypeProfessional Services
Description

Manufacturing of personalized mRNA cancer vaccines through collaboration with research institutions, utilizing microfluidic and robotics-based automation

research.arizona.edu
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Ntensify® mano
Description

RNA production technology for mano-scale applications

biotechniques.com
+2 more records
Core offering1 text field

Quantoom Biosciences develops and sells proprietary RNA production platforms (Ntensify® mano and Ntensify® micro) and LNP formulation kits (Ncapsulate®) used by researchers and institutions to produce and formulate RNA for therapeutic and vaccine development. The company also provides mRNA vaccine manufacturing services using microfluidic and robotics-based automation for personalized cancer vaccine programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Quantoom Biosciences offers a suite of RNA production and formulation technologies. The core products include the Ntensify® mano and Ntensify® micro RNA production platforms, which provide rapid RNA synthesis capabilities for research and therapeutic development. The portfolio is complemented by Ncapsulate® LNP formulation kits, which enable researchers to formulate and encapsulate RNA for delivery applications. Together, these products form an integrated workflow from RNA production to formulation for next-generation RNA therapeutics.

Product and service1 record
1Ntensify® mano
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-23
Description

Strategic distribution partnership for pan-European distribution of Quantoom's Ntensify® mano and Ntensify® micro RNA production technologies. The agreement expands Europa Biosite's portfolio in the rapidly growing RNA research field and is expected to extend to include Ncapsulate® LNP formulation kits as they become available. The companies aim to make high-quality RNA production and formulation tools more accessible to researchers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Collaboration to develop a novel personalized cancer vaccine framework using mRNA technology and AI. CAMI scientists identify tumor mutations and use AI algorithms to select neoantigen candidates, while Quantoom creates matching mRNA transcripts and manufactures vaccines using microfluidic and robotics-based automation. Initial testing planned in mouse models for melanoma with potential for individualized cancer treatments.

3University of Western Australia - RNA Innovation Foundry
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-12
Description

Strategic partnership making RNA Innovation Foundry the reference site for Quantoom Biosciences in Australia and the first in Oceania. The facility advances RNA-based medicine and biotech innovation, connecting academic research with industry practice. Also houses the Australian Centre for RNA Therapeutics in Cancer. Supported by Therapeutic Innovation Australia funding.

uwa.edu.au
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aldevron manufactures plasmid DNA, mRNA, and proteins for therapeutic developers, directly comparable to Quantoom's RNA production and LNP-formulation offerings.

TypeDirect peer
Description

eTheRNA is a Belgium-based mRNA technology and CDMO player developing RNA therapeutics and delivery platforms, comparable to Quantoom on geography, modality, and service offering.

TypeBroad incumbent
Description

CureVac is an established mRNA therapeutics company with proprietary RNA production technology and manufacturing capability, overlapping with Quantoom on RNA platform and CDMO-style operations.

TypeBroad incumbent
Description

GenScript provides gene synthesis, RNA services, and cell therapy manufacturing globally, with a broader portfolio but comparable RNA/customer-adjacent offerings to Quantoom.

TypeBroad incumbent
Description

BioNTech is a leading mRNA company with large-scale manufacturing and a broad pipeline including personalized cancer vaccines, putting it in adjacent competition with Quantoom's manufacturing-services offering.

TypeBroad incumbent
Description

Lonza is a global CDMO with established mRNA and lipid nanoparticle manufacturing services, representing the scaled incumbent against which Quantoom's automated RNA platform must compete for commercial customers.

TypeBroad incumbent
Description

Moderna operates one of the world's largest mRNA manufacturing footprints across vaccines and therapeutics, setting the benchmark for at-scale RNA production against which Quantoom's automation approach must compete.

TypeDirect peer
Description

Vernal is an mRNA CDMO offering research- and GMP-grade mRNA manufacturing and LNP formulation, directly overlapping Quantoom's Ntensify®/Ncapsulate® stack.

TypeDirect peer
Description

TriLink is a leading manufacturer of mRNA, oligonucleotides, and plasmid DNA for research and clinical use, and is Quantoom's closest functional peer in nucleic-acid production services and reagents.

TypeDirect peer
Description

IDT manufactures synthetic RNA and DNA oligonucleotides and serves RNA researchers with production tools, directly comparable to Quantoom's Ntensify® RNA production platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quantoom Biosciences

RNA Production Technologyquantoom.com

Quantoom Biosciences is a Belgium-based biotech that develops proprietary microfluidic and robotics-based RNA production and LNP formulation technologies, selling Ntensify® kits and Ncapsulate® reagents to academic and research customers developing mRNA vaccines and therapeutics.

What Quantoom Biosciences does

Quantoom Biosciences is a Belgium-based, privately held biotechnology company founded in 2021 that develops proprietary RNA production and formulation technologies for mRNA vaccine and therapeutic manufacturing. The company's core platform combines microfluidic and robotics-based automation with its registered Ntensify® product family — Ntensify® mano for research-scale RNA synthesis and Ntensify® micro for compact-scale workflows — and is being extended with Ncapsulate® LNP (lipid nanoparticle) formulation kits that encapsulate RNA for delivery. Together these products form an integrated RNA production-to-formulation workflow aimed at researchers developing next-generation RNA applications and therapeutics, with a particular emphasis on personalized cancer vaccines.

The company operates a hybrid revenue model anchored in hardware sales of its Ntensify® kits and Ncapsulate® LNP kits, supplemented by professional-services revenue from co-development and manufacturing collaborations in personalized mRNA cancer vaccines. Go-to-market is channel-led: a pan-European distribution partnership with Europa Biosite (announced March 2026) drives research-customer reach across Europe, while flagship academic reference-site partnerships — the RNA Innovation Foundry at the University of Western Australia (April 2025) and the University of Arizona Center for Advanced Molecular and Immunological Therapies (February 2026) — function as both validation anchors and co-development partners. The company is headquartered in Nivelles, Belgium, employs 101-250 people, and is led by CEO José Castillo.

Quantoom Biosciences firmographics

Firmographics
Name
Quantoom Biosciences
Website
https://quantoom.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Quantoom Biosciences is a Belgium-based biotech that develops proprietary microfluidic and robotics-based RNA production and LNP formulation technologies, selling Ntensify® kits and Ncapsulate® reagents to academic and research customers developing mRNA vaccines and therapeutics.
Ownership category
akta.pro rank

Quantoom Biosciences industry classification

Industry
Product category
RNA Production Technology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA production technology
  • MRNA manufacturing
  • Lipid nanoparticle formulation
  • Biotech research tools
  • Personalized cancer vaccines

Where Quantoom Biosciences is headquartered

Location

Headquarters

HQ city
Nivelles
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Quantoom Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. RNA Production Technologies: Sale and distribution of Ntensify® mano and Ntensify® micro RNA production technologies to researchers across Europe through distribution partnerships
  2. LNP Formulation Kits: Sale of Ncapsulate® LNP formulation kits for RNA delivery applications as they become commercially available
  3. mRNA Vaccine Manufacturing Services: Manufacturing of personalized mRNA cancer vaccines through collaboration with research institutions, utilizing microfluidic and robotics-based automation

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Quantoom Biosciences product offering

Product offering

Core offering

Quantoom Biosciences develops and sells proprietary RNA production platforms (Ntensify® mano and Ntensify® micro) and LNP formulation kits (Ncapsulate®) used by researchers and institutions to produce and formulate RNA for therapeutic and vaccine development. The company also provides mRNA vaccine manufacturing services using microfluidic and robotics-based automation for personalized cancer vaccine programs.

Product overview

Quantoom Biosciences offers a suite of RNA production and formulation technologies. The core products include the Ntensify® mano and Ntensify® micro RNA production platforms, which provide rapid RNA synthesis capabilities for research and therapeutic development. The portfolio is complemented by Ncapsulate® LNP formulation kits, which enable researchers to formulate and encapsulate RNA for delivery applications. Together, these products form an integrated workflow from RNA production to formulation for next-generation RNA therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • Ntensify® mano: RNA production technology for mano-scale applications
  • Ntensify® micro
  • Ncapsulate® LNP formulation kits

Products and services

  • Ntensify® mano

Companies that use Quantoom Biosciences

Customer profile

Named customers1 record

Segments2 records

Quantoom Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Quantoom Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • Europa BiositecoreChannel Partner/ Reseller/ Distributor · 23 March 2026Strategic distribution partnership for pan-European distribution of Quantoom's Ntensify® mano and Ntensify® micro RNA production technologies. The agreement expands Europa Biosite's portfolio in the rapidly growing RNA research field and is expected to extend to include Ncapsulate® LNP formulation kits as they become available. The companies aim to make high-quality RNA production and formulation tools more accessible to researchers.
  • University of Arizona - Center for Advanced Molecular and Immunological Therapies (CAMI)coreStrategic or Co-development Partner · 18 February 2026Collaboration to develop a novel personalized cancer vaccine framework using mRNA technology and AI. CAMI scientists identify tumor mutations and use AI algorithms to select neoantigen candidates, while Quantoom creates matching mRNA transcripts and manufactures vaccines using microfluidic and robotics-based automation. Initial testing planned in mouse models for melanoma with potential for individualized cancer treatments.
  • University of Western Australia - RNA Innovation FoundryflagshipStrategic or Co-development Partner · 12 April 2025Strategic partnership making RNA Innovation Foundry the reference site for Quantoom Biosciences in Australia and the first in Oceania. The facility advances RNA-based medicine and biotech innovation, connecting academic research with industry practice. Also houses the Australian Centre for RNA Therapeutics in Cancer. Supported by Therapeutic Innovation Australia funding.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Quantoom Biosciences competitors and assessment

Company assessment

Direct peers

  • Aldevron: Aldevron manufactures plasmid DNA, mRNA, and proteins for therapeutic developers, directly comparable to Quantoom's RNA production and LNP-formulation offerings.
  • eTheRNA immunotherapies: eTheRNA is a Belgium-based mRNA technology and CDMO player developing RNA therapeutics and delivery platforms, comparable to Quantoom on geography, modality, and service offering.
  • Vernal Biosciences: Vernal is an mRNA CDMO offering research- and GMP-grade mRNA manufacturing and LNP formulation, directly overlapping Quantoom's Ntensify®/Ncapsulate® stack.
  • TriLink BioTechnologies (Maravai LifeSciences): TriLink is a leading manufacturer of mRNA, oligonucleotides, and plasmid DNA for research and clinical use, and is Quantoom's closest functional peer in nucleic-acid production services and reagents.
  • Integrated DNA Technologies (IDT): IDT manufactures synthetic RNA and DNA oligonucleotides and serves RNA researchers with production tools, directly comparable to Quantoom's Ntensify® RNA production platforms.

Broad incumbents

  • CureVac: CureVac is an established mRNA therapeutics company with proprietary RNA production technology and manufacturing capability, overlapping with Quantoom on RNA platform and CDMO-style operations.
  • GenScript: GenScript provides gene synthesis, RNA services, and cell therapy manufacturing globally, with a broader portfolio but comparable RNA/customer-adjacent offerings to Quantoom.
  • BioNTech: BioNTech is a leading mRNA company with large-scale manufacturing and a broad pipeline including personalized cancer vaccines, putting it in adjacent competition with Quantoom's manufacturing-services offering.
  • Lonza: Lonza is a global CDMO with established mRNA and lipid nanoparticle manufacturing services, representing the scaled incumbent against which Quantoom's automated RNA platform must compete for commercial customers.
  • Moderna: Moderna operates one of the world's largest mRNA manufacturing footprints across vaccines and therapeutics, setting the benchmark for at-scale RNA production against which Quantoom's automation approach must compete.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Quantoom Biosciences social profiles

Digital presence

Quantoom Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quantoom Biosciences leadership team

Management profile

Number of profiles

Quantoom Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quantoom Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantoom Biosciences

What does Quantoom Biosciences do?

Quantoom Biosciences develops and sells proprietary RNA production platforms (Ntensify® mano and Ntensify® micro) and LNP formulation kits (Ncapsulate®) used by researchers and institutions to produce and formulate RNA for therapeutic and vaccine development. The company also provides mRNA vaccine manufacturing services using microfluidic and robotics-based automation for personalized cancer vaccine programs.

Is Quantoom Biosciences a public or private company?

Quantoom Biosciences is a private company. It is classified as unknown and is currently operating.

When was Quantoom Biosciences founded?

Quantoom Biosciences was founded in 2021. It employs 51 to 100 people.

Where is Quantoom Biosciences based?

Quantoom Biosciences is headquartered in Nivelles, Belgium, in the Europe region.

How does Quantoom Biosciences make money?

Three revenue lines are on record. RNA Production Technologies are the primary driver. The others are LNP Formulation Kits and mRNA Vaccine Manufacturing Services.

Who are Quantoom Biosciences's main competitors?

Direct peers on record are Aldevron, eTheRNA immunotherapies, Vernal Biosciences, TriLink BioTechnologies (Maravai LifeSciences) and Integrated DNA Technologies (IDT). Broad incumbents are CureVac, GenScript, BioNTech, Lonza and Moderna.

Does Quantoom Biosciences have an API?

No public API is recorded for Quantoom Biosciences.

What industry is Quantoom Biosciences in?

Quantoom Biosciences's product category is RNA Production Technology. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Arizona WETCollaboration aims to accelerate personalized cancer therapy developmentThe University of Arizona's Center for Advanced Molecular and Immunological Therapies has established a collaboration with Belgium-based Quantoom Biosciences to develop a novel personalized cancer vaccine framework using mRNA technology and AI. CAMI scientists will identify tumor mutations and use AI algorithms to select neoantigen candidates most likely to trigger an immune response, while Quantoom will create matching mRNA transcripts and manufacture vaccines using microfluidic and robotics-based automation. The partnership aims to accelerate cancer immunotherapy development with initial testing planned in mouse models for melanoma, with researchers emphasizing the potential for individualized treatments that activate the immune system against cancer cells.PharmiWeb.comAstraveus further strengthens world class leadership team to advance development of Lakhesys Benchtop Cell Factory™Astraveus SAS announced the appointment of Didier Masson as Chief Operating Officer and Ken Kotz as Chief Technology Officer to advance its Lakhesys Benchtop Cell Factory platform for cell therapy manufacturing. Didier Masson joins from Quantoom Biosciences with over 20 years of operations experience across pharma, biotech, and medtech, while Ken Kotz previously served as Director of Process Development at bluebird bio, contributing to the commercialization of the Lyfgenia cell therapy. The hirings follow earlier 2025 appointments of Jean-Paul Mangeolle as Chairman, David Newble as Independent Board Member, and Laurence Riot Lamotte as CFO, as the company positions itself to transform autologous cell and gene therapy manufacturing.UwaRNA Innovation Foundry to boost WA's role in next-gen biotechThe RNA Innovation Foundry was launched at The University of Western Australia to advance RNA-based medicine and biotech innovation, connecting academic research with real-world industry practice. The facility has established a strategic partnership with Belgium-based biotech company Quantoom Biosciences, becoming its reference site in Australia and the first in Oceania, while also housing the Australian Centre for RNA Therapeutics in Cancer. The initiative, supported by funding partner Therapeutic Innovation Australia, aims to boost Australia's global competitiveness in mRNA technology development, manufacturing, and workforce growth.PrwebQuantoom Biosciences and DIANT Pharma Inc. Collaborate to Enhance mRNA Supply Chain EfficiencyQuantoom Biosciences and DIANT Pharma Inc. announced a strategic collaboration to optimize the supply chain for messenger RNA (mRNA) through enhanced lipid nanoparticle (LNP) processing. The partnership combines Quantoom's mRNA production expertise with DIANT's LNP formulation technology to streamline manufacturing, improve yields, and increase accessibility to mRNA-based therapies globally.Business Wire BlogAfrica and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom BiosciencesEVA Pharma, DNA Script, and Quantoom Biosciences signed a MoU to develop an end-to-end mRNA production platform. The platform aims to produce 100 million doses annually and supports Africa CDC's 60% local vaccine production target by 2040.